Evidence map›Paper›PMID 30621633›Full record

ArticleBMC cancer2019

Geographical disparities in treatment and health care costs for end-of-life cancer patients in China: a retrospective study.

Anli Leng, Jun Jing, Stephen Nicholas, Jian Wang

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
10.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 46 citations in OpenAlex.

  1. Trial
  2. Structuring healthcare advance directives: Evidence from Chinese end-of-life cancer patients' treatment preferences.Health expectations : an international journal of public participation in health care and health policy · 2023
    Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

Anli LengCenter for Health Economics Experiment and Public Policy, School of Public Health, Shandong University, No. 44 Wenhuaxi Road, Lixia District, Jinan, 250012, China.
Jun JingResearch Center for Public Health, Tsinghua University, Room B408, Medical School, Beijing, 100084, China.
Stephen NicholasSchool of Economics and School of Management, Tianjin Normal University, West Bin Shui Avenue, Tianjin, 300074, China.
Jian WangCenter for Health Economics Experiment and Public Policy, School of Public Health, Shandong University, No. 44 Wenhuaxi Road, Lixia District, Jinan, 250012, China. wangjiannan@sdu.edu.cn.ORCID http://orcid.org/0000-0001-9539-2016
Shandong University · CNTianjin Normal University · CNTsinghua University · CN

Funding

China Scholarship Council 201706220244National Natural Science Foundation of China 71373146National Natural Science Foundation of China 71702131
6 · The paper itself

Abstract

backgroundCancer imposes substantial burdens on cancer suffers, their families and the health system, especially in the end of life (EOL) of care patients. There are few developing country studies of EOL health care costs and no specialist studies of the disparities in cancer treatment and care costs by geographical location in China. We sought to examine geographical disparities in the types of cancer treatments and care costs during the last 3 months of life for Chinese cancer patients.

methodsUsing snowball sampling and face-to-face interviews, field research was conducted with a specialist questionnaire. Data were collected on 792 cancer patients who died between July 2013 and June 2016 in China. Total EOL health care costs were modeled using generalized linear models (GLMs) with log link and gamma distribution.

resultsTotal health care costs were highest for urban (US$12,501) and western region (US$9808) patients and lowest for rural (US$5996) and central region (US$5814) patients. Our study revealed about 40% of the health care expenses occur in the last three months of life, and was mainly driven by hospital costs that accounted for about 70% of EOL expenditures. Patients faced out-of-pocket expenses for health care, with the ability to borrow from family and friends also impacting the type of treatment and health facility. Life-extending treatments per cancer patient was about two times that of patients receiving conservative treatments.Urban patients were more likely to receive life-extending treatments, financed by higher incomes and a greater capacity to borrow from family and friends to bridge the gap between health insurance reimbursements and out-of-pocket expenditures. Cancer patients in western region and urban area were significantly more likely to access hospice care.

conclusionsWe found significant urban-rural and regional disparities in EOL types of cancer treatment, utilization of medical care and the health care expenditures. The EOL cancer care costs imposed heavy economic burdens in China.We recommend better clinical guidelines, improved EOL conversations and fuller information on treatment regimes among patients, family caregivers and doctors. Policies and information should pay more attention to palliative care options and the socio-cultural context of cancer care decision-making by family.

Indexed as

Health Care CostsHealth ExpendituresAdultAgedAged, 80 and overChinaFemaleHospice CareHumansMaleMiddle AgedNeoplasmsPalliative CareRetrospective StudiesSurveys and QuestionnairesTerminal CareCancer treatmentsEnd-of-life (EOL)Geographic disparitiesHealth care costs

Identifiers

PMID30621633
PMCPMC6325809
OpenAlexW2910294144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.